Cargando…

Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health

Both safety and efficacy of medical treatment can vary depending on the ethnogeographic background of the patient. One of the reasons underlying this variability is differences in pharmacogenetic polymorphisms in genes involved in drug disposition, as well as in drug targets. Knowledge and appreciat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yitian, Lauschke, Volker M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177500/
https://www.ncbi.nlm.nih.gov/pubmed/34652573
http://dx.doi.org/10.1007/s00439-021-02385-x
_version_ 1784722901369356288
author Zhou, Yitian
Lauschke, Volker M.
author_facet Zhou, Yitian
Lauschke, Volker M.
author_sort Zhou, Yitian
collection PubMed
description Both safety and efficacy of medical treatment can vary depending on the ethnogeographic background of the patient. One of the reasons underlying this variability is differences in pharmacogenetic polymorphisms in genes involved in drug disposition, as well as in drug targets. Knowledge and appreciation of these differences is thus essential to optimize population-stratified care. Here, we provide an extensive updated analysis of population pharmacogenomics in ten pharmacokinetic genes (CYP2D6, CYP2C19, DPYD, TPMT, NUDT15 and SLC22A1), drug targets (CFTR) and genes involved in drug hypersensitivity (HLA-A, HLA-B) or drug-induced acute hemolytic anemia (G6PD). Combined, polymorphisms in the analyzed genes affect the pharmacology, efficacy or safety of 141 different drugs and therapeutic regimens. The data reveal pronounced differences in the genetic landscape, complexity and variant frequencies between ethnogeographic groups. Reduced function alleles of CYP2D6, SLC22A1 and CFTR were most prevalent in individuals of European descent, whereas DPYD and TPMT deficiencies were most common in Sub-Saharan Africa. Oceanian populations showed the highest frequencies of CYP2C19 loss-of-function alleles while their inferred CYP2D6 activity was among the highest worldwide. Frequencies of HLA-B*15:02 and HLA-B*58:01 were highest across Asia, which has important implications for the risk of severe cutaneous adverse reactions upon treatment with carbamazepine and allopurinol. G6PD deficiencies were most frequent in Africa, the Middle East and Southeast Asia with pronounced differences in variant composition. These variability data provide an important resource to inform cost-effectiveness modeling and guide population-specific genotyping strategies with the goal of optimizing the implementation of precision public health. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00439-021-02385-x.
format Online
Article
Text
id pubmed-9177500
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-91775002022-06-10 Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health Zhou, Yitian Lauschke, Volker M. Hum Genet Review Both safety and efficacy of medical treatment can vary depending on the ethnogeographic background of the patient. One of the reasons underlying this variability is differences in pharmacogenetic polymorphisms in genes involved in drug disposition, as well as in drug targets. Knowledge and appreciation of these differences is thus essential to optimize population-stratified care. Here, we provide an extensive updated analysis of population pharmacogenomics in ten pharmacokinetic genes (CYP2D6, CYP2C19, DPYD, TPMT, NUDT15 and SLC22A1), drug targets (CFTR) and genes involved in drug hypersensitivity (HLA-A, HLA-B) or drug-induced acute hemolytic anemia (G6PD). Combined, polymorphisms in the analyzed genes affect the pharmacology, efficacy or safety of 141 different drugs and therapeutic regimens. The data reveal pronounced differences in the genetic landscape, complexity and variant frequencies between ethnogeographic groups. Reduced function alleles of CYP2D6, SLC22A1 and CFTR were most prevalent in individuals of European descent, whereas DPYD and TPMT deficiencies were most common in Sub-Saharan Africa. Oceanian populations showed the highest frequencies of CYP2C19 loss-of-function alleles while their inferred CYP2D6 activity was among the highest worldwide. Frequencies of HLA-B*15:02 and HLA-B*58:01 were highest across Asia, which has important implications for the risk of severe cutaneous adverse reactions upon treatment with carbamazepine and allopurinol. G6PD deficiencies were most frequent in Africa, the Middle East and Southeast Asia with pronounced differences in variant composition. These variability data provide an important resource to inform cost-effectiveness modeling and guide population-specific genotyping strategies with the goal of optimizing the implementation of precision public health. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00439-021-02385-x. Springer Berlin Heidelberg 2021-10-15 2022 /pmc/articles/PMC9177500/ /pubmed/34652573 http://dx.doi.org/10.1007/s00439-021-02385-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Zhou, Yitian
Lauschke, Volker M.
Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health
title Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health
title_full Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health
title_fullStr Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health
title_full_unstemmed Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health
title_short Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health
title_sort population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177500/
https://www.ncbi.nlm.nih.gov/pubmed/34652573
http://dx.doi.org/10.1007/s00439-021-02385-x
work_keys_str_mv AT zhouyitian populationpharmacogenomicsanupdateonethnogeographicdifferencesandopportunitiesforprecisionpublichealth
AT lauschkevolkerm populationpharmacogenomicsanupdateonethnogeographicdifferencesandopportunitiesforprecisionpublichealth